Home   Business   Article

Optibrium appoints Clare Devlin as FD as it plots growth


By Paul Brackley


Drug discovery software company Optibrium has appointed Clare Devlin as financial director as it eyes expansion.

Clare Devlin, financial director at Optibrium. Picture: Optibrium (6966531)
Clare Devlin, financial director at Optibrium. Picture: Optibrium (6966531)

Clare, who held FD roles at Scintacor, Addviso and Genestack, arrives following the company’s move last year to Cambridge Innovation Park in Waterbeach, the recruitment of three more software engineers and the release of StarDrop 6.5, the latest version of its lead product.

CEO Dr Matthew Segall said: “The appointment of Clare and the strengthening of our software development team form part of ambitious growth plans and mission to accelerate our R&D pipeline. This will enable us to extend our research into new technologies that improve the efficiency and productivity of the drug discovery process.

“As the company matures, we’re investing in key senior and technical roles to maintain corporate development and help bring new product features to our clients quicker. I am delighted to welcome the new members of our multidisciplinary team.”

Clare said: “Optibrium’s rapid revenue growth in 2018 has set a great foundation for further growth this year. I look forward to assisting the company with their continued business development and corporate expansion.”



COMMENTS
()


Iliffe Media does not moderate comments. Please click here for our house rules.

People who post abusive comments about other users or those featured in articles will be banned.

Thank you. Your comment has been received and will appear on the site shortly.

 

Terms of Comments

We do not actively moderate, monitor or edit contributions to the reader comments but we may intervene and take such action as we think necessary, please click here for our house rules.

If you have any concerns over the contents on our site, please either register those concerns using the report abuse button, contact us here.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More